These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12620461)

  • 21. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical application of gonadotrophin for IVF-ET].
    Kajihara T; Ishihara O
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():237-41. PubMed ID: 16689315
    [No Abstract]   [Full Text] [Related]  

  • 26. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study.
    Westergaard LG; Erb K; Laursen SB; Rex S; Rasmussen PE
    Fertil Steril; 2001 Sep; 76(3):543-9. PubMed ID: 11532479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IGF-I and epidermal growth factor levels in follicular fluid of women undergoing controlled ovarian hyperstimulation using the multidose GnRH-antagonist protocol or the long GnRH-agonist protocol.
    Asimakopoulos B; Schöpper B; Dawson A; Caglar GS; Vakalopoulos I; Al-Hasani S; Diedrich K; Nikolettos N
    J Endocrinol Invest; 2006 May; 29(5):RC5-8. PubMed ID: 16794358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ultrashort flare GnRH-agonist/GnRH-antagonist protocol enables cycle programming and may overcome the "detrimental effect" of the oral contraceptive.
    Orvieto R
    Fertil Steril; 2012 Sep; 98(3):e17-8; author reply e19. PubMed ID: 22840381
    [No Abstract]   [Full Text] [Related]  

  • 29. First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization.
    Beckers NG; Macklon NS; Devroey P; Platteau P; Boerrigter PJ; Fauser BC
    Fertil Steril; 2003 Mar; 79(3):621-3. PubMed ID: 12620451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study.
    Stadtmauer LA; Sarhan A; Duran EH; Beydoun H; Bocca S; Pultz B; Oehninger S
    Fertil Steril; 2011 Jan; 95(1):216-20. PubMed ID: 20594551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can we skip weekends in GnRH antagonist cycles without compromising the final outcome?
    Bosch E
    Fertil Steril; 2012 Jun; 97(6):1299-300. PubMed ID: 22656307
    [No Abstract]   [Full Text] [Related]  

  • 33. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy.
    Kolibianakis EM; Albano C; Kahn J; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
    Fertil Steril; 2003 Apr; 79(4):873-80. PubMed ID: 12749423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments.
    Maldonado LG; Franco JG; Setti AS; Iaconelli A; Borges E
    Fertil Steril; 2013 May; 99(6):1615-22. PubMed ID: 23394779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study.
    Bodri D; Guillén JJ; Trullenque M; Schwenn K; Esteve C; Coll O
    Fertil Steril; 2010 May; 93(7):2418-20. PubMed ID: 19800620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle.
    Seelig AS; Al-Hasani S; Katalinic A; Schöpper B; Sturm R; Diedrich K; Ludwig M
    Fertil Steril; 2002 Mar; 77(3):472-5. PubMed ID: 11872197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval.
    Celik O; Celik E; Yilmaz E; Celik N; Turkcuoglu I; Ulas M; Kumbak B; Aktan E; Ozerol I
    Arch Gynecol Obstet; 2013 Dec; 288(6):1417-22. PubMed ID: 23801011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).
    Garcia-Velasco JA; Isaza V; Vidal C; Landazábal A; Remohí J; Simón C; Pellicer A
    Hum Reprod; 2001 Dec; 16(12):2533-9. PubMed ID: 11726570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.